Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC)
| Autor: | Johan Ahlgren, Minna Tanner, Riikka Huovinen, Heikki Joensuu, R. Kokko, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Henrik Lindman, Päivi Auvinen, Arja Jukkola-Vuorinen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 28:531-531 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 531 Background: Interim data from this phase III randomized trial (FinXX) evaluating the integration of capecitabine into anthracycline-/taxane-based adjuvant therapy for early BC were recently published (Lancet Oncol 2009); the present subgroup analysis explores the efficacy results in patients with triple-negative BC. Methods: 1,500 patients with axillary node-positive or high-risk node-negative (tumor size > 20 mm, progesterone receptor-negative) BC were randomized to the X-containing regimen: 3x XT (X 900 mg/m2 bid d1–14 and T 60 mg/m2 iv d1, q21d) followed by 3x CEX (C 600 mg/m2 iv d1, E 75 mg/m2 iv d1 and X 900 mg/m2 bid d1–14, q21d; n = 753), or the control regimen: 3x T (80 mg/m2 iv d1, q21d) followed by 3x CEF (C 600 mg/m2, E 75 mg/m2 and F 600 mg/m2 all d1, q21d; n = 747) in January 2004 to May 2007. The primary endpoint was recurrence-free survival (RFS) and the median follow-up time 3 yrs. Results: RFS was significantly increased with the X-containing therapy compared with control (92.5% vs. 8... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|